CCG Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

CCG Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,854	Closed	-$208K	–	131
2021 Q4	$208K	Hold	1,854	–	–	0.11%	89
2021 Q3	$233K	Hold	1,854	–	–	0.13%	89
2021 Q2	$251K	Buy	1,854 +122	+7%	+$16K	0.2%	59
2021 Q1	$235K	Hold	1,732	–	–	0.23%	58
2020 Q4	$244K	Sell	1,732 -484	-22%	-$62K	0.26%	63
2020 Q3	$247K	Sell	2,216 -260	-11%	-$29.1K	0.23%	44
2020 Q2	$277K	Sell	2,476 -447	-15%	-$44K	0.26%	35
2020 Q1	$226K	Sell	2,923 -12	-0.4%	-$1.06K	0.22%	52
2019 Q4	$279K	Buy	2,935 +243	+9%	+$21K	0.18%	70
2019 Q3	$205K	Buy	+2,692	New	+$224K	0.14%	82

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

CCG Wealth Management's XBI Position: Q1 2022 in Review

CCG Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 1,854 shares — an estimated $208K sold.

CCG Wealth Management first reported a position in XBI in Q3 2019 and held it in 10 quarters. The position peaked at $279K in Q4 2019. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

CCG Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
CCG Wealth Management sold 1,854 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $208K.
CCG Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2019 and held it in 10 quarters.
CCG Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $279K in Q4 2019.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on CCG Wealth Management's 13F filing for Q1 2022, filed 12 Apr 2022.